Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus

Annals of Medicine

Volumn 28, Issue 4, 1996, Pages 371-380

  Juhan Vague, Irène ^a   Alessi, Marie Christine ^a   Vague, Philippe ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Atherothrombosis; Diabetes mellitus; Factor VII; Fibrinogen; Fibrinolysis; Insulin resistance; Noninsulin dependent; Plasminogen activator inhibitor 1; Risk factors; Tissue plasminogen activator; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VON WILLEBRAND FACTOR;

ADIPOSE TISSUE; ARTICLE; BLOOD PRESSURE; BODY MASS; CORONARY ARTERY ATHEROSCLEROSIS; FIBRINOLYSIS; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENESIS;

EID: 0029822786     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899608999095     Document Type: Article

References (27)

1. Vaughan DE, Declerck PJ, Van Hote E, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost 1992; 68: 60-3.
2. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusion in mice transgenic for the plasminogen activator inhibitor 1 gene. Nature 1990; 346: 74-6.
3. Biemond BJ, Levi M, Coronel R, Janse MJ, Ten Gate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effect of plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 1995; 91: 1175-81.
4. Carmeliet P, Stassen JM, Schoonjans L, et al. Plasminogen activator inhibitor 1 gene-deficient mice. II Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993; 92: 2756-60.
5. Ernst E and Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
6. Thompson SG, Kienast J, Pyke SKM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
7. Smith EB. Fibrinogen, fibrin and fibrin degradation productions in relation to atherosclerosis. Clin Haematol 1986; 15: 355-70.
8. Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryk B, Kaplan KK. Identification and distribution of fibrinogen, fibrin and fibrin (ogen) degradation products in atherosclerosis. Arteriosclerosis 1989; 9: 109-21.
9. Lowe GD, Drummond MM, Lorimer AR, et al. Relation between extent of coronary artery disease and blood viscosity. BMJ 1980; 280: 673-4.
10. Hamsten A, Blombäck M, Wiman B, et al. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66.
11. Folsom AR, Wu KK, Shahar E, Davis CE, for the Atherosclerosis Risk in Communities (ARIC) Study investigators. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13: 1829-36.
12. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3,000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
13. Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15: 1245-50.
14. Ernst E. Fibrinogen: an important risk factor for atherothrombotic diseases. Ann Med 1994; 26: 15-22.
15. Ernst E. Does the reduction of body weight lower plasma fibrinogen levels. Br Heart J 1993; 70: 116-8.
16. Schmitz A, Ingerslev J. Hemostatic measurements in type II diabetic patients with albuminura. Diabetic Med 1990; 7: 521-5.
17. Neri S, Bruno CM, Raciti C, D'Angelo G, D'Amico R, Cristaldi R. Alteration of oxide reductive and haemostatic factors in type 2 diabetics. J Intern Med 1994; 236: 495-500.
18. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
19. Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
20. Heinrich J, Balleisen L, Schulte H, Assman G, Van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
21. Miller GJ, Martin JC, Webster J, et al. Association between dietary fat intake and plasma factor VII coagulant activity - a predictor of cardiovascular mortality. Atherosclerosis 1986; 60: 269-77.
22. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakada T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non insulin dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 7995 1114-20.
23. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. BMJ 1991; 66: 351-5.
24. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischemic heart disease. Br J Haematol 1994; 88: 601-7.
25. Haverkate F. Thrombosis and disabilities. In: Baya C, ed. Advances in Medical Biology, Amsterdam: IOS Press, 1994: 81-103.
26. Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Thromb Haemost 1995; 73: 561-7.
27. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor-1 and atherothrombosis. Thromb Haemost 1993; 70: 138-43.